Yungjin Pharm wins the 1st trial against Ofev
By Kim, Jin-Gu | translator Hong, Ji Yeon
24.12.31 05:44:43
가나다라
0
Indication including the clause 'excluding IPF' has been approved…MFDS acknowledges the 'exclusion clause' for the first time
Exclusion clause was a key to Yungjin Pharm's victory… will this become the new patent avoidance strategy?
Yungjin Pharm has won the usage patent dispute for Ofev (nintedanib), a treatment for idiopathic pulmonary fibrosis (IPF). Based on the victory, Yungjin is one step closer to the early launch of its generic version of Ofev.
The pharmaceutical industry suggests this decision is significant beyond Yungjin Pharmaceutical's avoidance of Ofev's usage patent. It may serve as a patent-avoidance strategy for generics.
Yungjin Pharm wins the first trial for Ofev's usage patent…brings closer to the early launch of generic
According to the pharmaceutical industry on December 20, the Korean Intellectual Property Trial and Appeal Board (IPTAB) recently issued a decision
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)